Skip to main content

Advertisement

SpringerLink
Log in

Reiseimpfungen für besondere Personengruppen

Travel vaccinations for certain groups of persons

  • Leitthema
  • Published:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Aims and scope

Zusammenfassung

Die Anzahl an Menschen, die internationale Reisen unternehmen, ist in den letzten Jahrzehnten stetig gestiegen. Unter den Reisenden befinden sich in zunehmendem Maß auch Menschen, bei denen ein erhöhtes Risiko für impfpräventable Infektionserkrankungen oder die Entwicklung von schwereren Krankheitsverläufen besteht.

Senioren, Kinder, Schwangere und Stillende, Personen mit besonderen Vorerkrankungen sowie Menschen, die in ihrem Herkunftsland Verwandte und Freunde besuchen (Visiting Friends and Relatives [VFR]), sind Risikogruppen, die bei der reisemedizinischen Vorsorge allgemein und besonders hinsichtlich empfohlener Impfungen besondere Beachtung verdienen. Bei einigen dieser Risikogruppen sind Einschränkungen bezüglich der Verträglichkeit oder der Wirksamkeit notwendiger Impfungen zu berücksichtigen.

Nicht zu allen Risikogruppen und jedem Impfstoff gibt es eine eindeutige Studienlage, sodass die Beratung vor einer Reise immer eine Einzelfallbetrachtung unter Abwägung von individuellem Nutzen und Risiko erfordert. Im vorliegenden Beitrag sind die Besonderheiten für jede Gruppe aufgeführt, die es grundsätzlich bei der reisemedizinischen Vorsorge zu beachten gilt.

Abstract

The number of international travelers has been continuously increasing in recent decades. Among travelers, there are more and more people at an increased risk for acquiring diseases that could be prevented by vaccines or for the development of a severe course of disease. Risk groups in travel medicine are senior travelers, children, pregnant and breast-feeding women, persons with pre-existing medical conditions, and persons who visit their friends and relatives abroad (VFR). Individuals in these groups require attention during pretravel advice consultations, particularly with regards to recommended vaccinations. On the other hand, for some risk groups, particular vaccines cannot be given for safety reasons or because the response to vaccines is reduced. Not all risk groups or each vaccine have sufficient evidence available, so each patient’s risks and benefits must be weighed during pretravel consultation. In this article, the particularities for each risk group with respect to pretravel immunization are highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Bialy C, Horne K, Dendle C et al (2015) International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. Intern Med J 45:618–623

    CAS  PubMed  Google Scholar 

  2. Hall V, Johnson D, Torresi J (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med. https://doi.org/10.1093/jtm/tay018

    Article  Google Scholar 

  3. Ständige Impfkommission (2019) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 34:313–364

    Google Scholar 

  4. Taylor DN, Pollard RA, Blake PA (1983) Typhoid in the United States and the risk to the international traveler. J Infect Dis 148:599–602

    CAS  PubMed  Google Scholar 

  5. Wagner A, Garner-Spitzer E, Jasinska J et al (2018) Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 8:9825

    PubMed  PubMed Central  Google Scholar 

  6. Lindsey NP, Horiuchi KA, Fulton C et al (2018) Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. https://doi.org/10.1093/jtm/tay108

    Book  Google Scholar 

  7. Borg MA, Tiemersma E, Scicluna E et al (2009) Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 15:232–237

    CAS  PubMed  Google Scholar 

  8. Gershman M, CDC (2018) Infectious diseases related to travel—yellow fever. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/yellow-fever. Zugegriffen: 04. Sept. 2019

  9. Smithburn K (1956) Reactions following vaccination against yellow fever. World Health Organization monograph series; no 30. https://apps.who.int/iris/handle/10665/41664 (143–189). Zugegriffen: 04. Sept. 2019

  10. Teitelbaum P, Committee to Advise on Tropical Medicine and Travel (CATMAT) (2018) Statement on the use of booster doses of yellow fever vaccine. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/use-booster-doses-yellow-fever-vaccine.html. Zugegriffen: 4. Sept. 2019

  11. Khatami A, Khan F, Macartney KK (2017) Enteric fever in children in western Sydney, Australia, 2003–2015. Pediatr Infect Dis J 36:1124–1128

    PubMed  Google Scholar 

  12. Zhou K, Sauve LJ, Richardson SE, Ford-Jones EL, Morris SK (2017) Enteric fever in a multicultural Canadian tertiary care pediatric setting: a 28-year review. J Pediatric Infect Dis Soc 6:98–101

    PubMed  Google Scholar 

  13. Badahdah AM, Rashid H, Khatami A, Booy R (2018) Meningococcal disease burden and transmission in crowded settings and mass gatherings other than Hajj/Umrah: a systematic review. Vaccine 36:4593–4602

    PubMed  Google Scholar 

  14. Carroll ID, Williams DC (2008) Pre-travel vaccination and medical prophylaxis in the pregnant traveler. Travel Med Infect Dis 6:259–275

    PubMed  Google Scholar 

  15. Anonymous (2018) ACOG Committee Opinion No. 741: maternal immunization. Obstet Gynecol 131:e214–e217

    Google Scholar 

  16. Nishioka Sde A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL (1998) Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 3:29–33

    PubMed  Google Scholar 

  17. Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA, The Campinas Group of Yellow Fever Immunization during Pregnancy (2007) Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12:833–837

    PubMed  Google Scholar 

  18. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, Campinas Group on Yellow Fever Immunization During Pregnancy (2006) The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24:1421–1426

    CAS  PubMed  Google Scholar 

  19. Centers for Disease Control and Prevention (2010) Transmission of yellow fever vaccine virus through breast-feeding—Brazil, 2009. Mmwr Morb Mortal Wkly Rep 59:130–132

    Google Scholar 

  20. Pharma K Medical GmbH (2016) Typhoral L Kapseln Fachinformation. https://www.fachinfo.de/api/fachinfo/pdf/021226. Zugegriffen: 04. Sept. 2019

  21. Casqueiro J, Casqueiro J, Alves C (2012) Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 16(Suppl 1):27–36

    Google Scholar 

  22. Dos Santos G, Tahrat H, Bekkat-Berkani R (2018) Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: a systematic review. Human Vaccines & Immunotherapeutics 14:1853–1866

    Google Scholar 

  23. Cheruvattath R, Balan V (2007) Infections in patients with end-stage liver disease. J Clin Gastroenterol 41:403–411

    PubMed  Google Scholar 

  24. Agarwal SK, Irshad M, Dash SC (1999) Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 47:183–185

    CAS  PubMed  Google Scholar 

  25. Daroza G, Loewen A, Djurdjev O et al (2003) Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 42:1184–1192

    PubMed  Google Scholar 

  26. Pesanti EL (2001) Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 15:813–832

    CAS  PubMed  Google Scholar 

  27. Mathew R, Mason D, Kennedy JS (2014) Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines 13:285–298

    CAS  PubMed  Google Scholar 

  28. Farez MF, Correale J (2011) Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 68:1267–1271

    PubMed  Google Scholar 

  29. Pool V, Gordon DM, Decker M (2012) Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination. Arch Neurol 69:144 (author reply 144–145)

    PubMed  Google Scholar 

  30. Hapfelmeier A, Gasperi C, Donnachie E, Hemmer B (2019) A large case-control study on vaccination as risk factor for multiple sclerosis. Neurology. https://doi.org/10.1212/WNL.0000000000008012

    Article  PubMed  Google Scholar 

  31. Lebrun C, Vukusic S, French Group for Recommendations in Multiple Sclerosis TSFDLSEP (2019) Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society. Rev Neurol 175:341–357

    CAS  PubMed  Google Scholar 

  32. Barwick Eidex R, Yellow Fever Vaccine Safety Working Group (2004) History of thymoma and yellow fever vaccination. Lancet 364:936

    PubMed  Google Scholar 

  33. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875–884

    CAS  PubMed  Google Scholar 

  34. Principi N, Esposito S (2018) Vaccine-preventable diseases, vaccines and Guillain-Barre’ syndrome. Vaccine. https://doi.org/10.1016/j.vaccine.2018.05.119

    Article  PubMed  Google Scholar 

  35. Lipowski D, Popiel M, Perlejewski K et al (2017) A cluster of fatal tick-borne encephalitis virus infection in organ transplant setting. J Infect Dis 215:896–901

    CAS  PubMed  Google Scholar 

  36. Steininger PA, Bobinger T, Dietrich W et al (2017) Two cases of severe tick-borne encephalitis in rituximab-treated patients in Germany: implications for diagnosis and prevention. Open Forum Infect Dis 4:ofx204

    PubMed  PubMed Central  Google Scholar 

  37. Burchard GD, Caumes E, Connor BA et al (2009) Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 16:204–216

    PubMed  Google Scholar 

  38. Varghese L, Curran D, Bunge E et al (2017) Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK. Public Health 142:46–49

    CAS  PubMed  Google Scholar 

  39. Ehl S, Bogdan C, Niehues T et al (2018) Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61:1034–1051

    Google Scholar 

  40. Rosdahl A, Herzog C, Frosner G, Noren T, Rombo L, Askling HH (2018) An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression—a prospective, open-label, multi-center study. Travel Med Infect Dis 21:43–50

    PubMed  Google Scholar 

  41. uk.gov (2016) Green Book. Meningococcal meningitis and septicaemia notifiable. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/554011/Green_Book_Chapter_22.pdf. Zugegriffen: 04. Sept. 2019

  42. Macneil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW (2016) Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons—advisory committee on immunization practices, 2016. Mmwr Morb Mortal Wkly Rep 65:1189–1194

    PubMed  Google Scholar 

  43. Australian Technical Advisory Group on Immunisation (Atagi) (2018) Australian Immunisation Handbook—Vaccination for people who are immunocompromised. In: Health AGDo (ed), Canberraimmunisationhandbook.health.gov.au. https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised. Zugegriffen: 04. Sept. 2019

  44. Mccarthy A, Committee to Advise on Tropical Medicine and Travel (CATMAT) (2015) Statement on meningococcal disease and the international traveller. Can Commun Dis Rep 41:100–107

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Garske T, Van Kerkhove MD, Yactayo S et al (2014) Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 11:e1001638

    PubMed  PubMed Central  Google Scholar 

  46. Leder K, Tong S, Weld L et al (2006) Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 43:1185–1193

    Google Scholar 

  47. Rowe K, Chaves N, Leder K (2017) Challenges to providing pre-travel care for travellers visiting friends and relatives: an audit of a specialist travel medicine clinic. J Travel Med. https://doi.org/10.1093/jtm/tax038

    Article  Google Scholar 

  48. Lammert SM, Rao SR, Jentes ES et al (2016) Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet. J Travel Med. https://doi.org/10.1093/jtm/taw075

    Book  Google Scholar 

  49. Faber MS, Stark K, Behnke SC, Schreier E, Frank C (2009) Epidemiology of hepatitis A virus infections, Germany, 2007–2008. Emerging Infect Dis 15:1760–1768

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Heywood AE, Zwar N, Forssman BL et al (2016) The contribution of travellers visiting friends and relatives to notified infectious diseases in Australia: state-based enhanced surveillance. Epidemiol Infect 144:3554–3563

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Nielsen US, Larsen CS, Howitz M, Petersen E (2009) Hepatitis A among Danish travellers 1980–2007. J Infect 58:47–52

    PubMed  Google Scholar 

  52. Van Genderen PJ, Van Thiel PP, Mulder PG, Overbosch D, Dutch Schiphol Airport Study Group (2012) Trends in knowledge, attitudes, and practices of travel risk groups toward prevention of hepatitis A: results from the Dutch Schiphol Airport survey 2002 to 2009. J Travel Med 19:35–43

    PubMed  Google Scholar 

  53. Lynch MF, Blanton EM, Bulens S et al (2009) Typhoid fever in the United States, 1999–2006. Jama 302:859–865

    CAS  PubMed  Google Scholar 

  54. Suryapranata FS, Prins M, Sonder GJ (2016) Low and declining attack rates of imported typhoid fever in the Netherlands 1997–2014, in spite of a restricted vaccination policy. BMC Infect Dis 16:731

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Heywood AE, Forssman BL, Seale H, Macintyre CR, Zwar N (2015) General practitioners’ perception of risk for travelers visiting friends and relatives. J Travel Med 22:368–374

    PubMed  Google Scholar 

  56. Hagmann S, Reddy N, Neugebauer R, Purswani M, Leder K (2010) Identifying future VFR travelers among immigrant families in the Bronx, New York. J Travel Med 17:193–196

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fachgebiet Impfprävention, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland

    Kerstin Kling &  Ole Wichmann

  2. Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Deutschland

    Gerd Burchard

  3. Ständige Impfkommission (STIKO), Berlin, Deutschland

    Gerd Burchard

Authors
  1. Kerstin Kling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ole Wichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerd Burchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerstin Kling.

Ethics declarations

Interessenkonflikt

K. Kling, O. Wichmann und G. Burchard geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kling, K., Wichmann, O. & Burchard, G. Reiseimpfungen für besondere Personengruppen. Bundesgesundheitsbl 63, 85–92 (2020). https://doi.org/10.1007/s00103-019-03067-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00103-019-03067-w

Schlüsselwörter

Keywords

Search

Navigation